Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

Table 1 Immune checkpoint inhibitor mAb therapies

mAb	Target	Structure	Isotype	Route of admin.	Approvals^a
Ipilimumab	CTLA-4	Fully human	IgG1, kappa	IV	MEL, RCC^b, MSI-H/MRD CRC^b
Nivolumab	PD-1	Fully human	IgG4, kappa	IV	MEL, NSCLC, cHL, RCC, HNSCC, UC, MSI-H/MRD CRC, HCC
Pembrolizumab	PD-1	Humanized	IgG4, kappa	IV	MEL, NSCLC, cHL, HNSCC, PMBCL, UC, MSI-H/MRD cancer, HCC, gastric cancer, cervical cancer
Cemiplimab	PD-1	Fully human	IgG4, kappa	IV	CSCC
Atezolizumab	PD-L1	Humanized Fc-engineered	IgG1, kappa	IV	UC, NSCLC
Avelumab	PD-L1	Fully human	IgG1, lambda	IV	MCC, UC
Durvalumab	PD-L1	Engineered human	IgG1, kappa	IV	UC, stage III NSCLC

CRC colorectal cancer, cHL classical Hodgkin lymphoma, CSCC cutaneous squamous-cell carcinoma, CTLA-4 cytotoxic T-lymphocyte associated protein 4, HCC hepatocellular carcinoma, HNSCC head and neck squamous cell carcinoma, IV intravenous, mAb monoclonal antibody, MCC Merkel cell carcinoma, MEL melanoma, MRD mismatch repair-deficient, MSI-H microsatellite instability-high, NSCLC non-small-cell lung cancer, PD-1 programmed death 1, PD-L1 PD-ligand 1, PMBCL primary mediastinal large B-cell lymphoma, RCC renal cell carcinoma, SC subcutaneous, UC urothelial carcinoma
^aListed approvals reflect US Food and Drug Administration approvals
^bIn combination with nivolumab